Stockscreener 앱 받기
3.02
0.67%
0.02
전일 마감가:
$3.00
열려 있는:
$3
하루 거래량:
60,120
Relative Volume:
1.26
시가총액:
$26.58M
수익:
$442.00K
순이익/손실:
$-30.46M
주가수익비율:
-0.6771
EPS:
-4.46
순현금흐름:
$-27.47M
1주 성능:
-1.95%
1개월 성능:
-27.05%
6개월 성능:
-47.11%
1년 성능:
-56.76%
1일 변동 폭
$2.8964
$3.08
1주일 범위
$2.76
$3.18
52주 변동 폭
$2.57
$9.20
Clene Inc Stock (CLNN) Company Profile
명칭
Clene Inc
전화
801-676-9695
주소
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
CLNN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.02 | 26.58M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
29.94 | 36.06B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
57.67 | 32.31B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.41 | 28.46B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
74.67 | 20.81B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
30.40 | 16.80B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-07-18 | 개시 | H.C. Wainwright | Buy |
| 2022-05-02 | 개시 | Canaccord Genuity | Buy |
| 2021-09-28 | 개시 | Oppenheimer | Outperform |
Clene Inc 주식(CLNN)의 최신 뉴스
Clene to Present at the Emerging Growth Conference | CLNN Stock News - GuruFocus
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
Clene to Present at the Emerging Growth Conference - Bluefield Daily Telegraph
Clene Unveils Latest ALS and MS Treatment Progress: Key Presentation Coming - Stock Titan
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Nanomedicines Market Generated Opportunities, Future Scope 2025-2032 | Abbott, CombiMatrix, Clene Nanomedicine - newstrail.com
Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright - Defense World
Clene reports MS patient improvements with CNM-Au8 treatment By Investing.com - Investing.com India
Clene announces evidence of remyelination, neuronal repair with CNM-Au8 - TipRanks
Clene reports MS patient improvements with CNM-Au8 treatment - Investing.com Australia
Breakthrough: New MS Drug Actually Repairs Brain Damage, Trial Data Shows 90% Success Rate - Stock Titan
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference - The Globe and Mail
CLNN stock touches 52-week low at $2.95 amid market challenges By Investing.com - Investing.com South Africa
CLNN stock touches 52-week low at $2.95 amid market challenges - Investing.com India
Clene to Present at the Jones Healthcare and Technology Innovation Conference - The Manila Times
Clene Reveals Latest ALS and MS Treatment Innovations at Major Healthcare Conference - Stock Titan
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com Australia
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Mi - GuruFocus
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - MarketScreener
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - Barchart.com
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - Stock Titan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo
Clene Inc. shareholder general resonance sells $12,091 in stock By Investing.com - Investing.com India
Clene Inc. shareholder general resonance sells $12,091 in stock - Investing.com
Dually-Listed Aerospace Stock Finds Premarket Success Following Key Announcement - The Globe and Mail
Top Nanotechnology Stocks To ConsiderMarch 15th - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN) - Defense World
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
H.C. Wainwright maintains Clene stock Buy rating, $31 target - Investing.com India
Clene Inc (CLNN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
0.11%
자본화:
|
볼륨(24시간):